Day One Biopharmaceuticals, Inc. (DAWN) reported Q4 Revenue ; Offers Guidance

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) reported Q4 Revenue for the quarter came in at $52.8 million versus the consensus estimate of $45.86 million.

GUIDANCE:

Day One Biopharmaceuticals, Inc. sees FY2026 revenue of $225-250 million, versus the consensus of $236.6 million.

For earnings history and earnings-related data on Day One Biopharmaceuticals, Inc. (DAWN) click here.

You May Also Be Interested In

• Dell’s earning report was bullish for Intel CPU demand, analyst says
• StoneX Reiterates Hold Rating on Old Dominion Freight Line (ODFL) on QTD Operating Metrics
• StoneX on Mama’s Creations (MAMA): 'We Remain High-Conviction Buyers'